January 24, 2015 11:44 PM ET

Pharmaceuticals

Company Overview of Alexion Antibody Technologies, Inc.

Company Overview

Alexion Antibody Technologies, Inc. engages in the development of human therapeutic antibodies for autoimmune and inflammatory disorders, cancer, and infectious diseases. Alexion Antibody Technologies, Inc. was formerly known as Prolifaron, Inc. and it changed its name in September 2000. The company was founded in 1997 and is based in San Diego, California. Alexion Antibody Technologies, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

3985 Sorrento Valley Boulevard

Suite A

San Diego, CA 92121

United States

Founded in 1997

Phone:

858-550-3490

Fax:

858-550-3498

Key Executives for Alexion Antibody Technologies, Inc.

President
Age: 57
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Seredigm Corp. United States
Chirologix Pharmaceuticals United States
Allosteros Therapeutics Inc. United States
Dual Therapeutics, LLC United States
Cure Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alexion Antibody Technologies, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.